Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
暂无分享,去创建一个
P. Kirchhof | M. Ezekowitz | J. Halperin | A. Breazna | J. Oldgren | N. Cater | C. Pollack | Paul Sanders | Judith Spahr | W. Petkun
[1] S. Connolly,et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. , 2015, The New England journal of medicine.
[2] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[3] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.
[4] G. Lip,et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. , 2015, American heart journal.
[5] A. Camm,et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. , 2014, European heart journal.
[6] Jun Zhu,et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.
[7] Hugh Calkins,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.
[8] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[9] G. Breithardt,et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.
[10] G. Breithardt,et al. Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial , 2012 .
[11] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[12] D. Singer,et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[13] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[14] S. Yusuf,et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.
[15] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[16] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[17] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[18] D. Levy,et al. Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.
[19] J. Mayet,et al. Anticoagulation for cardioversion of atrial fibrillation. , 2002, Minerva cardioangiologica.
[20] S M Nazarian,et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.
[21] F. Loop,et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. , 1992, Journal of the American College of Cardiology.
[22] Bernard Rosner,et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.
[23] O. Orning,et al. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. , 1969, The American journal of cardiology.
[24] Rimm,et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.